2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

653. Multiple Myeloma: Clinical and Epidemiological: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Omics Technologies, Pathology, Serologic Tests, Treatment Considerations, Combination Therapy, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Radiation Therapy, Workforce, Adverse Events, Artificial Intelligence (AI), Deep Learning, Biological Processes, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Bleeding and Clotting, Thromboembolism, Immunology, Immunodeficiency, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

2224 Frontline treatment patterns and subsequent stem cell transplant utilization among US veterans with multiple myeloma

Byron Seiya Sigel, MSc, Cynthia Ruoqi Dong, BA2, Han Zhao3, Mei Wang, MSc4, Mark A Fiala, PhD5, Lawrence Liu, MD6, Kristen Marie Sanfilippo, MD, MPHS7, Theodore Thomas, MD8, Martin Schoen, MD, PMH9, Su-Hsin Chang, PhD10
1 Washington University School of Medicine, St Louis, Missouri, United States
2 Washington University School of Medicine, St Louis, Missouri, United States
3 St. Louis Veterans Affairs Medical Center, St Louis, Missouri, United States, Washington University School of Medicine, Saint Louis, Missouri, United States
4 St. Louis Veterans Affairs Medical Center, St Louis, Missouri, United States, Washington University School of Medicine, Saint Louis, Missouri, United States
5 St. Louis Veterans Affairs Medical Center, St Louis, Missouri, United States, Washington University School of Medicine, St Louis, Missouri, United States
6 Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, United States, St. Louis Veterans Affairs Medical Center, St Louis, Missouri, United States
7 St. Louis Veterans Affairs Medical Center, St Louis, Missouri, United States, Washington University School of Medicine, St Louis, Missouri, United States
8 St. Louis Veterans Affairs Medical Center, St Louis, Missouri, United States, Washington University School of Medicine, St Louis, Missouri, United States
9 Saint Louis University School of Medicine, Saint Louis, Missouri, United States, St. Louis Veterans Affairs Medical Center, St Louis, Missouri, United States
10 St. Louis Veterans Affairs Medical Center, St Louis, Missouri, United States, Washington University School of Medicine, Saint Louis, Missouri, United States

Introduction

Hematopoietic stem cell transplantation (HSCT) remains a standard treatment for eligible patients with multiple myeloma (MM), but the role of upfront HSCT is evolving as newer therapeutic regimens have been introduced. The widespread adoption of anti-CD38-based quadruplet therapy has transformed frontline treatment, yet real-world frontline treatment patterns according to subsequent HSCT remain incompletely characterized. Using nationwide data from the Veterans Health Administration (VHA), the largest integrated healthcare system in the United States, we characterized frontline treatment patterns according to subsequent HSCT and overall HSCT utilization among US Veterans with MM.

Methods

We identified Veterans in the VHA from 2015 to 2025 with ≥1 record of first-line MM-specific treatment (daratumumab, bortezomib, carfilzomib, lenalidomide, thalidomide, melphalan, or isatuximab). The index date was defined as the first MM-specific treatment. Frontline treatments were defined as therapies initiated within 60 days of the index date. Treatments and HSCT were captured using VA inpatient and outpatient pharmacy files, inpatient and outpatient procedure records for injectable agents, Fee Basis and Community Care data, and CMS Medicare Part D claims. Patients who underwent  HSCT before the index date were excluded. Baseline characteristics, frontline treatment patterns, transplant utilization, time to transplantation, and age-stratified analyses (<70 vs. ≥70 years) were summarized.

Results

We identified 3,870 Veterans who initiated frontline MM therapy between 2015 and 2025. Overall, 738 (19.1%) subsequently underwent HSCT, with annual utilization ranging from 11.8-27.3%. Median time from treatment initiation to HSCT was 248 days (IQR, 181-358). The mean age (62.6 vs. 72.5 years) and Charlson Comorbidity Index scores (5.7 vs. 6.9) were lower among transplant recipients than those who did not undergo transplantation. HSCT utilization was 20.4% among non-Hispanic Black Veterans, 27.4% among Hispanic Veterans, and 17.4% among non-Hispanic White Veterans. Frontline treatment patterns differed by subsequent transplant status. Compared with non-HSCT recipients, bortezomib (86.9% vs. 74.2%) and lenalidomide use (73.7% vs. 62.4%) were more common among transplant recipients. Triplet lenalidomide-bortezomib-dexamethasone (RVd) was the most common regimen overall and was more frequent among transplant recipients than non-recipients (42.4% vs. 26.7%). Among frontline regimens evaluated, patients receiving daratumumab-RVd had the highest subsequent HSCT utilization (37.0%). Compared with transplant recipients, non-HSCT patients more frequently received less intensive regimens, including lenalidomide-dexamethasone doublet therapy (9.6% vs. 2.4%). When stratified by age, HSCT utilization was 34.0% among patients aged <70 years compared with 7.7% among those aged ≥70 years. Patients aged <70 years had higher HSCT utilization following RVd (42.9% vs. 13.8%), daratumumab-RVd (51.1% vs. 19.0%), and lenalidomide-dexamethasone (17.6% vs. 0.9%) than those aged ≥70 years.

Conclusions

In the nationwide VHA, 19.1% underwent HSCT following frontline treatment for MM. Transplant recipients more commonly received triplet or quadruplet proteasome inhibitor- and immunomodulatory drug-based frontline therapy, whereas non-recipients more often received less intensive regimens, consistent with contemporary treatment approaches for transplant-eligible and transplant-ineligible patients. Younger patients were more likely to undergo HSCT following RVd and daratumumab-RVd therapy, whereas HSCT utilization remained lower among patients aged ≥70 years across evaluated frontline regimens. These findings characterize contemporary frontline treatment patterns and HSCT utilization and may inform future studies evaluating treatment selection.

Byron Seiya Sigel, MSc: No relevant conflicts of interest to declare.